Lu-177 DOTATATE
Phase 2Small molecule
Lu-177 DOTATATE is one of 49 small molecule programs targeting Trial. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
133 competitors in Trial
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Herceptin
RochePhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Camptosar
PfizerPhase 3
Eloxatin
TevaPhase 3
Vectibix
AmgenPhase 3
Perjeta
RochePhase 3
Tarceva
OOSI Pharmaceuticals
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lu-177 DOTATATE. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity College, London